



TCIEXPRESS

LEADER IN EXPRESS

Dated: January 01, 2026

Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street-Mumbai-400001 Scrip Code: 540212	Listing Department National Stock Exchange of India Ltd. Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai-400051 Scrip Symbol: TCIEXP
--	---

Sub: Newspaper Publication
Ref: Notice for transfer of equity shares of the Company to IEPF

Dear Sir/Madam,

Please find attached copies of notices published today in the Nav Telangana and Financial Express newspapers, in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These notices pertain to the transfer of equity shares of the Company, along with shares/dividend lying in TCI Express Limited – Unclaimed Suspense Account 2018-19, Batch No. 8, concerning 2nd interim dividend declared in the financial year 2018-19, which have not been paid or claimed for seven consecutive years, to the Investor Education and Protection Fund ('IEPF') Authority.

Please be informed that the reminders letters in this regard, are also being sent to the shareholders regarding intimation about unclaimed shares and dividend due for transfer to the IEPF, pursuant to the provisions of Section 124 of the Companies Act, 2013 read with the IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.

Kindly acknowledge receipt and include this information in your records.

Thanking you,
For TCI Express Limited

PRIYANKA
(Company Secretary & Compliance Officer)
Encl: as above

TCI Express Limited
Website: www.tciexpress.in

Corporate Office: Plot No. 84, 3rd Floor, Sector 32, Institutional Area, Gurugram - 122001, India
Tel.: +91-124-2384090-94 • **Email:** info@tciexpress.in • **CIN:** L62200TG2008PLC061781
Registered Office: Flat Nos. 306 & 307, 1-8-273, Third Floor, Ashoka Bhoopal Chambers,
S. P. Road, Secunderabad – 500003 • **Tel.:** ++91 40 27840104

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS"). NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") IN COMPLIANCE WITH CHAPTER II OF THE SEBI ICDR REGULATIONS.

PUBLIC ANNOUNCEMENT



(Please scan this QR code to view the DRHP)



G. SURGIWEAR LIMITED

Our Company was incorporated as 'G. Surgiwear Private Limited', as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated July 11, 1990, issued by the Registrar of Companies, Uttar Pradesh at Kanpur ("RoC"). Thereafter, pursuant to a resolution passed by our Board on February 9, 1995 and a special resolution passed by our Shareholders on March 4, 1995, our Company was converted into a public limited company and consequently, the name of our Company was changed to 'G. Surgiwear Limited'. Consequently, a fresh certificate of incorporation consequent upon conversion to public company was issued by the Registrar of Companies, Uttar Pradesh at Kanpur on April 4, 1995. For further details regarding the change of name and registered office of our Company, please see "History and Certain Corporate Matters" on page 253 of the draft red herring prospectus dated December 30, 2025 (the "DRHP" or the "Draft Red Herring Prospectus").

Corporate Identity Number: U24236UP1990PLC012073

Registered and Corporate Office: Village Rasoolpur, Jehanganj, Shahjahanpur – 242 001, Uttar Pradesh, India
Contact Person: Piyush Chandra Seth, Company Secretary and Compliance Officer; Telephone: +91 75185 03415
E-mail: ad@surgiwear.net; Website: www.surgiwear.co.in

OUR PROMOTERS: GHANSHYAM DAS AGARWAL, RENU AGARWAL, VINAMRA AGARWAL, RISHU AGARWAL, GHANSHYAM DAS AGARWAL HUF

INITIAL PUBLIC OFFERING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF ₹[•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING TO ₹ 7,400.00 MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING UP TO ₹ 3,700.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING UP TO ₹ 3,700.00 MILLION ("OFFERED SHARES") BY GHANSHYAM DAS AGARWAL (THE "PROMOTER SELLING SHAREHOLDER") ("OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER"). THE OFFER SHALL CONSTITUTE [•] OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL.

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER AN ISSUE OF SPECIFIED SECURITIES, AS MAY BE PERMITTED UNDER APPLICABLE LAW, TO ANY PERSON(S), AGGREGATING UP TO ₹ 740.00 MILLION AT ITS DISCRETION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC ("PRE-IPO PLACEMENT"). THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SCRR. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20.00% OF THE SIZE OF THE FRESH ISSUE. OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. OUR COMPANY SHALL REPORT ANY PRE-IPO PLACEMENT TO THE STOCK EXCHANGES, WITHIN 24 HOURS OF SUCH PRE-IPO PLACEMENT (IN PART OR IN ENTIRETY). FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS.

THE FACE VALUE OF THE EQUITY SHARES IS ₹10 EACH. THE OFFER PRICE IS [•] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND, AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS AND WILL BE ADVERTISED IN ALL EDITIONS OF [•], A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER, ALL EDITIONS OF [•], A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, HINDI ALSO BEING THE REGIONAL LANGUAGE OF UTTAR PRADESH WHERE OUR REGISTERED AND CORPORATE OFFICE IS LOCATED, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO THE STOCK EXCHANGES FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES, IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI ICDR REGULATIONS").

In case of any revision in the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, in consultation with the BRLMs, and for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of one Working Days, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and by intimation to the Designated Intermediaries and the Sponsor Banks, as applicable.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50.00% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs", and such portion, "QIB Portion") provided that our Company may, in consultation with the BRLMs, allocate up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which up to 40% of the Anchor Investor Portion shall be reserved in the following manner: (i) 33.33% to domestic Mutual Funds and; (ii) 6.67% to Life Insurance Companies and Pension Funds, subject to valid Bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription under clause (ii), the allocation shall be made to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Offer shall be available for allocation to Non-Institutional Bidders out of which (a) one third of such portion shall be reserved for applicants with application size of more than ₹0.20 million and up to ₹1.00 million; and (b) two third of such portion shall be reserved for applicants with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders. Further, not less than 35.00% of the Offer shall be available for allocation to Retail Individual Bidders ("RIBs") in accordance with the SEBI ICDR Regulations, subject to valid Bids received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Accounts and UPI ID in case of UPI Bidders using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, please refer to the section titled "Offer Procedure" on page 409 of the DRHP.

This public announcement is made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing to undertake, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offer of its Equity Shares pursuant to the Offer and has filed the DRHP dated December 30, 2025 with SEBI and the Stock Exchanges on December 30, 2025.

Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with Securities and Exchange Board of India ("SEBI") shall be made available to the public for comments, if any, for period of at least 21 days, from the date of publication of this public announcement by hosting it on the website of SEBI at www.sebi.gov.in, on the websites of the Stock Exchanges i.e., BSE at www.bseindia.com and NSE at www.nseindia.com, respectively where the equity shares are proposed to be listed, the websites of the BRLMs, i.e., Motilal Oswal Investment Advisors Limited at www.motilalosalwainvest.com and Nuvama Wealth Management Limited at www.nuvama.com and the website of our Company at www.surgiwear.co.in. Our Company hereby invites the public to give their comments on the DRHP filed with SEBI, with respect to disclosures made in the DRHP. The members of public are requested to send a copy of their comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein below. All comments must be received by SEBI and/or our Company and/or the BRLMs and/or the Company Secretary and Compliance Officer of our Company at their respective addresses mentioned herein below in relation to the Offer on or before 5.00 p.m. on the 21st day from the aforesaid date of publication of this public announcement in accordance with Regulation 26(2) of SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares have not been recommended or approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 33 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be made after the red herring prospectus ("Red Herring Prospectus") has been filed with the RoC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the DRHP.

The Equity Shares, when offered through the Red Herring Prospectus, are proposed to be listed on the main board of the Stock Exchanges.

For details of the main objects of the Company as contained in its memorandum of association, see "History and Certain Corporate Matters" on page 253 of the DRHP.

The liability of the members of the Company is limited. For details of the share capital, capital structure of the Company and the names of the signatories to the memorandum of association and the number of shares subscribed by them see "Capital Structure" on page 91 of the DRHP.

BOOK RUNNING LEAD MANAGERS		REGISTRAR TO THE OFFER
Motilal Oswal Investment Advisors Limited Motilal Oswal Tower, Rahimullah Sayani Road Opposite Panel ST Depot, Prabhadevi Mumbai 400 025. Maharashtra, India Telephone: + 91 22 7193 4380 E-mail: gsi ipo@motilalosalwainvest.com Investor grievance e-mail: moaipl.redressal@motilalosalwainvest.com Website: www.motilalosalwainvest.com Contact person: Vaibhav Shah/ Sankita Ajinkya SEBI registration no.: INM000011005	Nuvama Wealth Management Limited 801 - 804, Wing A, Building No 3, Inspire BKC G Block, Bandra Kurla Complex, Bandra East Mumbai 400 051, Maharashtra, India Telephone: + 91 22 4009 4400 E-mail: gsurgwear.ipo@nuvama.com Investor grievance e-mail: customerservice.mb@nuvama.com Website: www.nuvama.com Contact person: Pari Vaya/Parthvi Shah SEBI registration no.: INM000013004	Bigshare Services Private Limited S6-2, 6th Floor, Pinnacle Business Park Mahakali Caves Road, Next to Ahura Centre Andheri (East), Mumbai 400 093, Maharashtra, India Telephone: +91 22 6263 8200 E-mail: ipo@bigshareonline.com Investor grievance e-mail: investor@bigshareonline.com Website: www.bigshareonline.com Contact person: Babu Raphael C SEBI registration number: INR000001385
COMPANY SECRETARY AND COMPLIANCE OFFICER		
Piyush Chandra Seth, G. SURGIWEAR LIMITED Village Rasoolpur, Jehanganj, Shahjahanpur – 242 001, Uttar Pradesh, India Telephone: +91 75185 03415; E-mail: piyush.cs@surgiwear.net; Website: www.surgiwear.co.in		

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For G. SURGIWEAR LIMITED
On behalf of the Board of Directors
Sd/-

Place: Shahjahanpur
Date : December 31, 2025

Piyush Chandra Seth
Company Secretary and Compliance Officer

G. SURGIWEAR LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offer of its Equity Shares and has filed the DRHP dated December 30, 2025 filed with SEBI and the Stock Exchanges on December 30, 2025. The DRHP shall be available on the website of SEBI at www.sebi.gov.in, on the websites of the Stock Exchanges i.e., BSE at www.bseindia.com and NSE at www.nseindia.com respectively, on the websites of the BRLMs, i.e., Motilal Oswal Investment Advisors Limited at www.motilalosalwainvest.com and Nuvama Wealth Management Limited at www.nuvama.com and on the website of our Company at www.surgiwear.co.in. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see the section titled "Risk Factors" on page 33 of the DRHP. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction, including India. The Equity Shares have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in "offshore transactions" as defined in and in reliance on, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made.

CONCEPT

TCI EXPRESS LIMITED
CIN: L62200TG2008PLC061781
Regd. Office : Flat Nos. 306 & 307, 1-8-271 to 273, Ashoka Bhupal Chambers,
S.P. Road, Secunderabad - 500 003, Telangana
Corp. Office : Plot No. 84, 3rd Floor, Institutional Area, Sector-32, Gurugram-122001, Haryana
Tel.: + 91 124 2384090-94, E-mail: secretarial@tcieexpress.in, Website: www.tcieexpress.in

NOTICE

TRANSFER OF EQUITY SHARES TO THE INVESTOR EDUCATION AND PROTECTION FUND (IEPF) AUTHORITY

For Kind Attention of Equity Shareholders

Notice is hereby given that, pursuant to the provisions of Companies Act, 2013 ("the Act") and the IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules"), equity shares of those Members, who have not claimed/encashed dividend for last seven consecutive years or more, commencing from the 2nd interim dividend for the FY 2018-19 along with shares/dividend lying in TCI Express Limited – Unclaimed Suspense Account 2018-19, Batch No. 8, are liable to be transferred by the Company to the demat account of IEPF authority (Authority).

Adhering to the requirement of the Act and IEPF Rules, individual notice and reminders being sent to the concerned shareholders, whose dividend and equity shares associated with said dividend, are liable to be transferred to the Authority on **March 20, 2026**. The Company has also uploaded the full details of such shareholders on its website at www.tcieexpress.in. The Shareholders are requested again to claim the dividend and equity shares including all benefits occurring on such shares on or before **March 10, 2026**, by making application to the Company.

Any claim made after the above-mentioned date shall be considered invalid and will not be taken on record and no claim shall lie against the Company thereafter and, with a view to comply with the aforesaid IEPF Rules, the Company shall transfer the unclaimed dividend (along with corresponding equity shares of dividend) to the demat account of IEPF authority, as per procedure set out under the Rules.

The Shareholders may note that unclaimed dividend and equity shares listed to said dividend, can be claimed back from the IEPF authority, after complying with the procedure set out in IEPF Rules.

In case the Shareholders have any queries on the subject matter, they may contact to the Company or its Registrar and Transfer Agents (RTA) as per given particulars:

Name	TCI Express Limited (Company)	KFin Technologies Limited (RTA)
Address	Plot No. 84, 3rd Floor, Sector 32, Institutional Area, Gurugram-122001	Selenium Tower B, Plot 31-32 Gachibowli, Financial District Nanakramguda, Hyderabad-500032
Contact	Tel: 91-124-238-4090-94	Tel: 040 - 67161621, 67161500
E-mail	secretarial@tcieexpress.in	einward.ris@kfinitech.com

For TCI Express Limited

Place: Gurugram
Date: December 31, 2025
Priyanka
Company Secretary and Compliance Officer

ICICI Prudential Asset Management Company Limited
Corporate Identity Number: U99999DL1993PLC054135

Registered Office: 12th Floor, Narain Manzil, 23, Barakhamba Road, New Delhi - 110 001.
Corporate Office: ICICI Prudential Mutual Fund Tower, Vakola, Santacruz East, Mumbai – 400 055; Tel: +91 22 6647 0200/2652 5000 Fax: +91 22 6666 6582/83, Website: www.icicipruamc.com, Email id: enquiry@icicipruamc.com
Central Service Office: 2nd Floor, Block B-2, Nirlon Knowledge Park, Western Express Highway, Goregaon (E), Mumbai - 400 063. Tel: 022 2685 2000 Fax: 022 26868313

Notice to the Investors/Unit holders of ICICI Prudential Equity-Arbitrage Fund, ICICI Prudential Multi-Asset Fund, ICICI Prudential Large Cap Fund (erstwhile Bluechip Fund) and ICICI Prudential Business Cycle Fund (the Schemes)

Notice is hereby given that ICICI Prudential Trust Limited, Trustee to ICICI Prudential Mutual Fund has approved the following distribution under Income Distribution cum capital withdrawal option (IDCW option) of the Schemes, subject to availability of distributable surplus on the record date i.e. on January 5, 2026*:

Name of the Schemes/Plans	Quantum of IDCW (₹ per unit) (Face value of ₹ 10/- each) [#]	NAV as on December 30, 2025 (₹ Per unit)
ICICI Prudential Equity-Arbitrage Fund		
IDCW	0.0500	15.2486
Direct Plan – IDCW	0.0500	17.5317
ICICI Prudential Multi-Asset Fund		
IDCW	0.1600	36.0227
Direct Plan – IDCW	0.1600	60.8735
ICICI Prudential Large Cap Fund (erstwhile Bluechip Fund)		
IDCW	2.70	33.57
Direct Plan – IDCW	2.70	66.53
ICICI Prudential Business Cycle Fund		
IDCW	1.60	19.81
Direct Plan – IDCW	1.60	21.28

\$ The distribution will be subject to the availability of distributable surplus and may be lower depending upon the extent of distributable surplus available on the record date under the IDCW option of the Schemes.

Subject to deduction of applicable statutory levy, if any.

* or the immediately following Business Day, if that day is a Non – Business Day.

The distribution with respect to IDCW will be done to all the unit holders/beneficial owners whose names appear in the register of unit holders/Statement of beneficial owners maintained by the Depositories, as applicable under the IDCW option of the Schemes, at the close of business hours on the record date.

It should be noted that pursuant to payment of IDCW, the NAV of the IDCW option of the Schemes would fall to the extent of payout and statutory levy (if applicable).

For ICICI Prudential Asset Management Company Limited
Place: Mumbai
Date : December 31, 2025
No. 001/01/2026

Sd/-
Authorised Signatory

To know more, call 1800 222 999/1800 200 6666 or visit www.icicipruamc.com
Investors are requested to periodically review and update their KYC details along with their mobile number and email id.
To increase awareness about Mutual Funds, we regularly conduct Investor Awareness Programs across the country. To know more about it, please visit https://www.icicipruamc.com or visit AMFI's website https://www.amfiindia.com
Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Dr. Agarwal's Eye Hospital Ltd.
CIN No. L85110TN1994PLC027366
Registered Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greaves Road, Chennai-600006.
Tel: 91-44-43787777, Email: investor@dragarwal.com, Website: www.dragarwal.com

NOTICE

Notice is hereby given that pursuant to SEBI Circular SEBI/HO/MIRSD/DOS3/CIR/P/2018/139 dated 6th November 2018 and SEBI Circular SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated 2nd July, 2025, a request for transfer has been received by the Company from Mr. Deepakkumar V Rathni, residing at Rathi Kirana & Gen, Shivaji Vesh, Khamgaon - 444 303 to transfer the below mentioned securities held in the name(s) of the security holder(s) as detailed below, and Mr. Deepakkumar V Rathni is in the process of applying to Investor Education and Protection Fund (IEPF) Authority for refund of the shares and dividends transferred to IEPF.

Folio No.	Name(s) of the Holder(s) registered address	Security Type and face value	No. of Securities	Distinctive Nos. From To
857	Virkumar Jain 4, Kanakshri Nagar, Colony, Cathdral Road, Madras - 600086.	Equity shares of Rs. 10/- face value	100	02438901-02439000

This notice is being issued as per Schedule III of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2017, as amended from time to time.

Any person who has a claim in respect of the above mentioned securities, should lodge such claim with the Company at its Registered Office within 30 days from this date along with appropriate documentary evidence thereof in support of such claim, else the Company will proceed to issue Entitlement letter in favour of Mr. Deepakkumar V Rathni, without any further intimation.

Dr. Agarwal's Eye Hospital Limited
Meenakshi Jayaraman
Company Secretary

Place : Chennai
Date : 31.12.2025

THE BIGGEST CAPITAL ONE CAN POSSESS KNOWLEDGE

FINANCIAL EXPRESS
Read to Lead

epaper.financialexpress.com

HYDERABAD

[illegible]